This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2001 Feb 3;322(7281):257.

Doctors suspended after injecting wrong drug into spine

C Dyer

PMID: 11157519
PMCID: PMC1119519

Case Reports

Doctors suspended after injecting wrong drug into spine

C Dyer. BMJ. 2001.

. 2001 Feb 3;322(7281):257.

Author

C Dyer

PMID: 11157519
PMCID: PMC1119519

No abstract available

PubMed Disclaimer

Figures

Figure
Pharmacy staff are instructed to dilute vincristine to at least 10 ml. The larger size syringe is meant to alert doctors to the fact that it should not be injected intrathecally (see box)

See this image and copyright information in PMC

Similar articles

Not again! Erroneous intrathecal injection results from a problem with protocols.
Seale JR. Seale JR. BMJ. 2001 Mar 3;322(7285):548. BMJ. 2001. PMID: 11230084 No abstract available.
Preventing vincristine sulfate medication errors.
Schulmeister L. Schulmeister L. Oncol Nurs Forum. 2004 Sep 17;31(5):E90-8. doi: 10.1188/04.ONF.E90-E98. Print 2004 Sep. Oncol Nurs Forum. 2004. PMID: 15378106 Review.
Simple method to eliminate the risk of inadvertent intrathecal vincristine administration.
Stefanou A, Dooley M. Stefanou A, et al. J Clin Oncol. 2003 May 15;21(10):2044; author reply 244. doi: 10.1200/JCO.2003.99.022. J Clin Oncol. 2003. PMID: 12743160 No abstract available.
Inadvertent intrathecal administration of vincristine: has anything changed?
Gilbar P. Gilbar P. J Oncol Pharm Pract. 2012 Mar;18(1):155-7. doi: 10.1177/1078155210396396. Epub 2011 Sep 29. J Oncol Pharm Pract. 2012. PMID: 21965437 No abstract available.
Intrathecal vincristine: an analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention.
Fernandez CV, Esau R, Hamilton D, Fitzsimmons B, Pritchard S. Fernandez CV, et al. J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):587-90. doi: 10.1097/00043426-199811000-00022. J Pediatr Hematol Oncol. 1998. PMID: 9856687 Review.

See all similar articles

Cited by

How safe is the safety paradigm?
Arah OA, Klazinga NS. Arah OA, et al. Qual Saf Health Care. 2004 Jun;13(3):226-32. doi: 10.1136/qhc.13.3.226. Qual Saf Health Care. 2004. PMID: 15175496 Free PMC article. Review.
Health Care Failure Mode and Effect Analysis: a useful proactive risk analysis in a pediatric oncology ward.
van Tilburg CM, Leistikow IP, Rademaker CM, Bierings MB, van Dijk AT. van Tilburg CM, et al. Qual Saf Health Care. 2006 Feb;15(1):58-63. doi: 10.1136/qshc.2005.014902. Qual Saf Health Care. 2006. PMID: 16456212 Free PMC article.
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics.
Straehla JP, Reardon DA, Wen PY, Agar NYR. Straehla JP, et al. Annu Rev Cancer Biol. 2023 Apr;7:265-289. doi: 10.1146/annurev-cancerbio-061421-040433. Epub 2023 Jan 25. Annu Rev Cancer Biol. 2023. PMID: 38323268 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information